Jaguar Health Inc. has entered into amendments to several existing royalty interest agreements with Iliad Research and Trading, L.P., Uptown Capital, LLC, and Streeterville Capital, LLC. Under the revised terms, beginning April 1, 2026, the company will be required to make a minimum monthly royalty payment of $750,000 or the actual royalty payment amount owed, whichever is greater, to each investor. Additionally, Jaguar Health and its subsidiary, Napo Pharmaceuticals, have amended a secured promissory note with Streeterville Capital, extending its maturity date to April 1, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-287650), on November 19, 2025, and is solely responsible for the information contained therein.
Comments